Circulating Tumor Cells in Myeloma: Can a Blood Test Predict High-Risk Disease? | IMS 2026

Luca Bertamini, MD, PhD, of Erasmus MC discusses circulating tumor cells for diagnosing, monitoring and assessing risk in myeloma at IMS 2026 in Glasgow. He explains how myeloma cells in the blood are measured with flow cytometry, and why higher numbers are linked to more aggressive disease, high-risk genetics and worse outcomes. Viewers will also learn how research across European centers is defining a useful cutoff and where plasma cell leukemia fits on this spectrum.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.